Ferring acquires licensing rights for Albireo’s elobixibat for irritable bowel
07:06 EDT 3 Jul 2012 | CentreWatch
Swiss research-driven specialty biopharmaceutical group Ferring Pharmaceuticals and Swedish biotech Albireo have signed a license agreement under which Ferring has rights to develop and commercialize elobixibat, a first-in-class compound for chronic..
Original Article: Ferring acquires licensing rights for Albireo’s elobixibat for irritable bowel
More From BioPortfolio on "Ferring acquires licensing rights for Albireo’s elobixibat for irritable bowel"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
